Therefore, the activation of cGAS‐STING mediated by a CDH11 inhibitor offers specific advantages, as it selectively targets tumor tissue when administered systemically, eliciting an antitumor immune response within the tumor microenvironment, while minimizing the side effects on normal tissue. This evidence concerns the gene CGAS and neoplasm.